Variable |
| Value |
Age (years), mean ± SD (range) |
| 48 ± 11 (24 to 73) |
Menopausal status | Premenopausal | 69 (60.0%) |
Postmenopausal | 46 (40.0%) | |
Weight (kg), mean ± SD (range) |
| 81 ± 13 (50 to 99) |
Height (cm), mean ± SD (range) |
| 156 ± 5 (145 to 170) |
BMI (kg/m2), mean ± SD (range) |
| 33.8 ± 6.0 (19.5 to 44.0) |
BMI, n (%) | ≤30 kg/m2 | 31 (27.0%) |
>30 kg/m2 | 84 (73.0%) | |
BSA (m2), mean ± SD (range) |
| 1.84 ± 0.15 (1.40 to 2.00) |
BSA, n (%) | ≤1.6 m2 | 16 (13.9%) |
>1.6 m2 | 99 (86.1%) | |
BSA, n (%) | ≤1.85 m2 | 48 (41.7%) |
>1.85 m2 | 67 (58.3%) | |
Comorbidities, n (%) | No comorbidity | 101 (89.4%) |
Comorbidity | 12 (10.6%) | |
Side, n (%) | Left side | 51 (44.3%) |
Right side | 64 (55.7%) | |
Surgery, n (%) | NA | 15 (13.0%) |
| MRM | 54 (47.0%) |
| BCS | 46 (40.0%) |
T stage, n (%) | T1/T2 | 70 (60.9%) |
| T3/T4 | 45 (39.1%) |
N stage, n (%) | N0/N1 | 70 (60.9%) |
| N2/N3 | 45 (39.1%) |
TNM stage, n (%) | Stage I/II | 49 (42.6%) |
| Stage III | 66 (57.4%) |
ER, n (%) | ER− | 27 (23.5%) |
| ER+ | 88 (76.5%) |
PR, n (%) | PR− | 39 (33.9%) |
| PR+ | 76 (66.1%) |
HER2, n (%) | HER2− | 85 (73.9%) |
| HER2+ | 30 (26.1%) |
Molecular subtype, n (%) | HR+ | 69 (60.0%) |
| HR+/HER2− | 18 (15.7%) |
| HER2+ | 12 (10.4%) |
| TN | 16 (13.9%) |